JP2020505049A - 複数トランスジーン組み換えアデノウイルス - Google Patents

複数トランスジーン組み換えアデノウイルス Download PDF

Info

Publication number
JP2020505049A
JP2020505049A JP2019541188A JP2019541188A JP2020505049A JP 2020505049 A JP2020505049 A JP 2020505049A JP 2019541188 A JP2019541188 A JP 2019541188A JP 2019541188 A JP2019541188 A JP 2019541188A JP 2020505049 A JP2020505049 A JP 2020505049A
Authority
JP
Japan
Prior art keywords
recombinant adenovirus
seq
nucleotides
deletion
site
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2019541188A
Other languages
English (en)
Japanese (ja)
Other versions
JP2020505049A5 (enExample
Inventor
アール． リード，トニー
アール． リード，トニー
ティー． オロンスキー，ブライアン
ティー． オロンスキー，ブライアン
ラーソン，クリストファー
Original Assignee
エピセントアールエックス，インコーポレイテッド
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by エピセントアールエックス，インコーポレイテッド filed Critical エピセントアールエックス，インコーポレイテッド
Publication of JP2020505049A publication Critical patent/JP2020505049A/ja
Publication of JP2020505049A5 publication Critical patent/JP2020505049A5/ja
Pending legal-status Critical Current

Links

Images

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N7/00—Viruses; Bacteriophages; Compositions thereof; Preparation or purification thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/66—Microorganisms or materials therefrom
    • A61K35/76—Viruses; Subviral particles; Bacteriophages
    • A61K35/761—Adenovirus
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C07K14/70503—Immunoglobulin superfamily
    • C07K14/70525—ICAM molecules, e.g. CD50, CD54, CD102
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C07K14/70503—Immunoglobulin superfamily
    • C07K14/70532—B7 molecules, e.g. CD80, CD86
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C07K14/70575—NGF/TNF-superfamily, e.g. CD70, CD95L, CD153, CD154
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
    • C12N15/85—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
    • C12N15/86—Viral vectors
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
    • C12N2710/00011—Details
    • C12N2710/10011—Adenoviridae
    • C12N2710/10311—Mastadenovirus, e.g. human or simian adenoviruses
    • C12N2710/10321—Viruses as such, e.g. new isolates, mutants or their genomic sequences
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
    • C12N2710/00011—Details
    • C12N2710/10011—Adenoviridae
    • C12N2710/10311—Mastadenovirus, e.g. human or simian adenoviruses
    • C12N2710/10332—Use of virus as therapeutic agent, other than vaccine, e.g. as cytolytic agent
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
    • C12N2710/00011—Details
    • C12N2710/10011—Adenoviridae
    • C12N2710/10311—Mastadenovirus, e.g. human or simian adenoviruses
    • C12N2710/10341—Use of virus, viral particle or viral elements as a vector
    • C12N2710/10343—Use of virus, viral particle or viral elements as a vector viral genome or elements thereof as genetic vector
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2840/00—Vectors comprising a special translation-regulating system
    • C12N2840/20—Vectors comprising a special translation-regulating system translation of more than one cistron
    • C12N2840/203—Vectors comprising a special translation-regulating system translation of more than one cistron having an IRES

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Genetics & Genomics (AREA)
  • Immunology (AREA)
  • General Health & Medical Sciences (AREA)
  • Zoology (AREA)
  • Medicinal Chemistry (AREA)
  • Biochemistry (AREA)
  • Molecular Biology (AREA)
  • Biophysics (AREA)
  • Engineering & Computer Science (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Cell Biology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Toxicology (AREA)
  • Virology (AREA)
  • Wood Science & Technology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Microbiology (AREA)
  • Biotechnology (AREA)
  • General Engineering & Computer Science (AREA)
  • Biomedical Technology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Mycology (AREA)
  • Epidemiology (AREA)
  • Physics & Mathematics (AREA)
  • Plant Pathology (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Management, Administration, Business Operations System, And Electronic Commerce (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
JP2019541188A 2017-01-30 2018-01-30 複数トランスジーン組み換えアデノウイルス Pending JP2020505049A (ja)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US201762452342P 2017-01-30 2017-01-30
US62/452,342 2017-01-30
US201762520945P 2017-06-16 2017-06-16
US62/520,945 2017-06-16
PCT/US2018/016032 WO2018140973A1 (en) 2017-01-30 2018-01-30 Multiple transgene recombinant adenovirus

Publications (2)

Publication Number Publication Date
JP2020505049A true JP2020505049A (ja) 2020-02-20
JP2020505049A5 JP2020505049A5 (enExample) 2021-03-11

Family

ID=62978741

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2019541188A Pending JP2020505049A (ja) 2017-01-30 2018-01-30 複数トランスジーン組み換えアデノウイルス

Country Status (12)

Country Link
US (1) US20190352616A1 (enExample)
EP (1) EP3574090A4 (enExample)
JP (1) JP2020505049A (enExample)
KR (1) KR20190128634A (enExample)
CN (1) CN110741080A (enExample)
AU (1) AU2018213417A1 (enExample)
BR (1) BR112019015600A2 (enExample)
CA (1) CA3052090A1 (enExample)
IL (1) IL268291A (enExample)
MX (1) MX2019008921A (enExample)
SG (1) SG11201906973TA (enExample)
WO (1) WO2018140973A1 (enExample)

Families Citing this family (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2903582C (en) 2013-03-14 2021-06-08 Salk Institute For Biological Studies Oncolytic adenovirus compositions
JP7015551B2 (ja) 2016-02-23 2022-02-15 ソーク インスティテュート フォー バイオロジカル スタディーズ ウイルス動態への影響を最小限にするための治療用アデノウイルスにおける外因性遺伝子発現
WO2017147265A1 (en) 2016-02-23 2017-08-31 Salk Institute For Biological Studies High throughput assay for measuring adenovirus replication kinetics
CA3045892A1 (en) 2016-12-12 2018-06-21 Salk Institute For Biological Studies Tumor-targeting synthetic adenoviruses and uses thereof
EA201990822A1 (ru) 2017-04-12 2020-01-09 Эписентарикс, Инк. Иммуномодулирующие слитые белки
EP3630959A4 (en) * 2017-05-24 2021-03-17 EpicentRx, Inc. ANTI-ANGIOGENIC ADENOVIRUS
BR112020019942A2 (pt) 2018-04-09 2021-01-26 Salk Institute For Biological Studies composições de adenovírus oncolítico com propriedades de replicação aprimoradas
WO2022007800A1 (zh) * 2020-07-06 2022-01-13 嘉兴安宇生物科技有限公司 一种非洲猪瘟的重组腺病毒疫苗及其构建方法
CN113249342B (zh) * 2021-05-25 2023-12-01 江苏万戎生物医药科技有限公司 一款多重机制协同和增效免疫治疗的嵌合型广谱溶瘤腺病毒及其在肿瘤治疗中的应用
WO2022246646A1 (zh) * 2021-05-25 2022-12-01 江苏万戎生物医药科技有限公司 一款多重机制协同和增效免疫治疗的嵌合型广谱溶瘤腺病毒及其在肿瘤治疗中的应用
EP4554559A1 (en) 2022-07-13 2025-05-21 EpicentRx, Inc. Adenoviral vectors encapsulated in cationic liposomes, and preparation and use thereof

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2012519014A (ja) * 2009-03-02 2012-08-23 ザ リージェンツ オブ ザ ユニバーシティ オブ カリフォルニア 腫瘍選択的ｅ１ａおよびｅ１ｂ変異体
JP2014500004A (ja) * 2010-09-24 2014-01-09 オンコス セラピュティックス オサケ ユキチュア 抗ｃｔｌａ−４モノクローナル抗体をコードする腫瘍溶解性アデノウイルスベクター

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR100896483B1 (ko) * 2007-07-13 2009-05-08 연세대학교 산학협력단 Ｉｌ-12 및 4-1ｂｂｌ을 발현하는 종양 선택적 살상 재조합아데노바이러스 및 수지상 세포를 유효성분으로 포함하는항종양용 약제학적 조성물
JP2013527753A (ja) * 2010-03-23 2013-07-04 イントレキソン コーポレーション 治療タンパク質を条件的に発現するベクター、該ベクターを含む宿主細胞およびそれらの使用
SG10201913795TA (en) * 2012-02-02 2020-03-30 Univ Texas Adenoviruses expressing heterologous tumor-associated antigens
WO2014170389A1 (en) * 2013-04-18 2014-10-23 Tilt Biotherapeutics Oy Enhanced adoptive cell therapy
CN103614416B (zh) * 2013-09-30 2016-09-07 中国人民解放军第二军医大学东方肝胆外科医院 一种携带人穿膜肽p53与GM-CSF基因的重组溶瘤腺病毒及其用途
DK3198009T3 (da) * 2014-09-24 2021-11-22 Salk Inst For Biological Studi Onkolytiske tumorvira og anvendelsesfremgangsmåder
US10232053B2 (en) * 2016-12-30 2019-03-19 Trieza Therapeutics, Inc. Immunomodulatory oncolytic adenoviral vectors, and methods of production and use thereof for treatment of cancer

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2012519014A (ja) * 2009-03-02 2012-08-23 ザ リージェンツ オブ ザ ユニバーシティ オブ カリフォルニア 腫瘍選択的ｅ１ａおよびｅ１ｂ変異体
JP2014500004A (ja) * 2010-09-24 2014-01-09 オンコス セラピュティックス オサケ ユキチュア 抗ｃｔｌａ−４モノクローナル抗体をコードする腫瘍溶解性アデノウイルスベクター

Non-Patent Citations (5)

* Cited by examiner, † Cited by third party
Title
BUKCZYNSKI, J. ET AL.: "Enhancement of HIV-specific CD8 T cell responses by dual costimulation with CD80 and CD137L", J. IMMUNOL., vol. Vol. 175(10), JPN7021005106, 2005, pages 6378 - 6389, ISSN: 0004647188 *
PONNAZHAGAN, S. ET AL.: "Adeno-associated virus 2-mediated antiangiogenic cancer gene therapy: long-term efficacy of a vector", CANCER RES., vol. Vol. 64(5), JPN7021005109, 2004, pages 1781 - 1787, ISSN: 0004841908 *
SALUCCI, V. ET AL.: "Adenovirus transduction and culture conditions affect the immunogenicity of murine dendritic cells", SCAND. J. IMMUNOL., vol. Vol. 62(3), JPN7021005110, 2005, pages 206 - 217, ISSN: 0004841907 *
SMALL, J. C. ET AL.: "Construction and characterization of E1- and E3-deleted adenovirus vectors expressing two antigens f", HUM. GENE THER., vol. Vol. 25(4), JPN7021005108, 2014, pages 328 - 338, ISSN: 0004841909 *
WEN, X. Y. ET AL.: "Tricistronic viral vectors co-expressing interleukin-12 (1L-12) and CD80 (B7-1) for the immunotherap", CANCER GENE THER., vol. Vol. 8(5), JPN7021005107, 2001, pages 361 - 370, ISSN: 0004647189 *

Also Published As

Publication number Publication date
CN110741080A (zh) 2020-01-31
WO2018140973A1 (en) 2018-08-02
KR20190128634A (ko) 2019-11-18
MX2019008921A (es) 2019-11-08
CA3052090A1 (en) 2018-08-02
EP3574090A1 (en) 2019-12-04
AU2018213417A1 (en) 2019-08-15
EP3574090A4 (en) 2021-01-06
SG11201906973TA (en) 2019-08-27
IL268291A (en) 2019-09-26
BR112019015600A2 (pt) 2020-03-17
US20190352616A1 (en) 2019-11-21

Similar Documents

Publication Publication Date Title
JP2020505049A (ja) 複数トランスジーン組み換えアデノウイルス
US12291726B2 (en) A549 host cells comprising a recombinant oncolytic adenovirus with modified E1A cancer-specific promoter
US12036247B2 (en) Multiple transgene recombinant adenovirus
JP7242534B2 (ja) 腫瘍選択的なｔａｔａボックスおよびｃａａｔボックスの変異体
US20200155625A1 (en) Anti-angiogenic adenovirus
US20250388930A1 (en) Tumor selective tata-box and caat-box mutants
EP2021034A2 (en) An isolated dna fragment of the human a33 promoter and its use to control the expression of a heterologous gene in tumor cells
HK40018033B (en) Tumor selective tata-box and caat-box mutant oncolytic viruses
HK40018033A (en) Tumor selective tata-box and caat-box mutant oncolytic viruses

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20210127

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20210127

A977 Report on retrieval

Free format text: JAPANESE INTERMEDIATE CODE: A971007

Effective date: 20211111

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20211126

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20220225

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20220331

A02 Decision of refusal

Free format text: JAPANESE INTERMEDIATE CODE: A02

Effective date: 20220803